(Q33544590)

27 July 2017

1 reference

title

Oral micronized progesterone (English)

1 reference

27 July 2017

de Lignières B

1

1 reference

27 July 2017

publication date

1 January 1999

1 reference

27 July 2017

published in

Clinical Therapeutics

1 reference

27 July 2017

volume

21

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

41-60; discussion 1-2

1 reference

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Hormone replacement therapy and endometrial cancer: are current regimens safe?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Estradiol and progesterone regulate the proliferation of human breast epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Hormone replacement therapy and biological aggressiveness of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Prognostic characteristics in breast cancers after hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

HRT and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Effects of estrogen and progestin on aortic size and compliance in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Progesterone inhibits arterial smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Estrogen and progesterone inhibit vascular smooth muscle proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Progesterone implants enhance SIV vaginal transmission and early virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Absorption of oral progesterone is influenced by vehicle and particle size

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone*†*Supported in part by a grant from Besins-Iscovesco, Paris, France.†Presented in part at the 35th Annual Mee

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Influence of route of administration on progesterone metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Comparative bioavailability of orally and vaginally administered progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Kinetics of norethindrone in women. II. Single-dose kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

L-norgestrel and progesterone have different influences on plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Tamoxifen and natural progesterone as supplements to low-dose postmenopausal estrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Regional adipose tissue metabolism in postmenopausal women after treatment with exogenous sex steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Changes in Plasma Lipoprotein and Apolipoprotein Composition in Relation to OralVersusPercutaneous Administration of Estrogen Alone or in Cyclic Association with Utrogestan in Menopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Natural progesterone and antihypertensive action.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Hormone replacement therapy and risk of non-fatal stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Vascular endothelial growth factor expression in cycling human endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Prostanoids and catecholamines after oral administration of natural progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Progesterone and the premenstrual syndrome: a double blind crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The effects of oral administration of progesterone for premature labor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

The use of micronized progesterone in the treatment of menace of preterm delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

Intrahepatic cholestasis of pregnancy: a French prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988267-3

7 January 2021

10.1016/S0149-2918(00)88267-3

Identifiers

DOI

1 reference

27 July 2017

1 reference